Clik here to view.
Clik here to view.
Theorem Clinical Research Expands Leadership and Prepares for Growth with...
KING OF PRUSSIA, Pa. Theorem Clinical Research, a leading contract research organization that optimizes trial conduct, has named Kathryn Bohannon as vice president of biopharmaceutical development...
View ArticleClik here to view.
Ascom Establishes Distribution in Mexico
RESEARCH TRIANGLE PARK, N.C. Ascom (US), Inc., a leading provider of mission-critical healthcare communication solutions, is pleased to announce its establishment of distribution into Mexico. A key...
View ArticleClik here to view.
KineMed获得经费，将其测量肌肉质量的新方法应用于婴儿及儿童营养不良和生长迟缓的诊断及预防
加州爱莫利维尔 (美国商业资讯) — KineMed, Inc. (www.kinemed.com)今天宣布获得比尔和梅林达·盖茨基金会一笔为期3年的经费，将其测量骨骼肌质量的无创专利新方法应用于早产及足月婴儿和幼儿。主要研究者William...
View ArticleClik here to view.
Taro to Announce Second Quarter Results on November 9, 2014
HAWTHORNE, N.Y. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for the quarter and six months ended September 30, 2014, on Sunday,...
View ArticleClik here to view.
資生堂、国際化粧品技術者会（IFSCC）で5大会連続・世界最多、通算19回目の「最優秀賞」を受賞
東京 （ビジネスワイヤ） — 資生堂は、2014年10月28～30日 パリ（フランス）で開催された、世界の化粧品技術者が集う化粧品に関する科学領域で最も権威のある研究発表会｢第28回国際化粧品技術者会大会｣（28th IFSCC※1 Congress）で、ポスター発表部門の｢最優秀賞｣を受賞しました。 今回の最優秀賞は、第24～27回に続く5大会連続、また大会（IFSCC...
View ArticleClik here to view.
资生堂第19次荣获国际化妆品化学家学会联盟（IFSCC）“最优秀奖”–成为连续5年·世界获奖最多企业
东京 (美国商业资讯)– 世界化妆品技术者云集，以发表在化妆品和肌肤相关的世界最高水平的研究成果为目的的第28届国际化妆品化学家学会联盟28th IFSCC※1 Congress 于2014年10月28日～30日在巴黎举行。资生堂在海报发表组中获得了“最优秀奖”。 资生堂自第24-27届的IFSCC Congress (含IFSCCConference)...
View ArticleClik here to view.
Shiseido Wins the 5th Consecutive Top Award and Garners 19 Awards in Total to...
TOKYO Shiseido Co., Ltd. (TOKYO:4911) won the “Top Award” in the Poster Presentation category at the “28th IFSCC*1 Congress” held on October 28 – 30, 2014 in Paris, France. IFSCC Congresses are...
View ArticleClik here to view.
GVK BIOがVanta Bioscience買収の正式契約を締結
印ハイデラバード （ビジネスワイヤ） — アジア一流の創薬研究開発組織であるGVK BIOは、Vanta Bioscienceを買収するための正式契約の締結を発表しました。Vanta Bioscienceは、インドのチェンナイを拠点にフルサービスの前臨床GLP毒性／安全性評価を手掛ける受託研究機関です。 Vanta BioscienceはOECDのGLP、ISO、USFDAのGLP（21...
View ArticleClik here to view.
Global Kinetics Corporation Achieves Key Milestones for Expansion
LONDON Australian mobile health technology company Global Kinetics Corporation announced today that it has appointed Swedish regulatory affairs veteran Dr Thomas Lönngren to the Board of Directors,...
View ArticleClik here to view.
GVK BIO Signs Definitive Agreement to Acquire Vanta Bioscience
HYDERABAD, India Asia’s leading Discovery Research and Development organization, GVK BIO, announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP...
View ArticleClik here to view.
Leading Chinese Research Institute Purchases Provantis Preclinical Software...
CONSHOHOCKEN, Pa. Instem, a leading provider of IT solutions to the global early development healthcare market, is pleased to announce that the Shanghai Institute of Planned Parenthood Research...
View ArticleClik here to view.
GVK BIO签署收购 Vanta Bioscience的确定性协议
印度海德拉巴德 (美国商业资讯) — 亚洲领先的发现和研发组织GVK BIO宣布签署收购Vanta Bioscience的确定性协议，Vanta是一家总部位于印度钦奈的合同研究组织，提供临床前GLP毒理学和安全性评估全套服务。 Vanta 符合OECD GLP、ISO、USFDA GLP (21 CFR Part 58 rev....
View ArticleClik here to view.
Taiyo Pacific Partners成为Peptidream, Inc.的主要股东，所持股份超过5%
东京 –(美国商业资讯)–Taiyo Pacific Partners今天宣布，该公司已累计持有Peptidream, Inc. (4587) 5%以上的股份，成为Peptidream的第二大机构股东。Peptidream渴望成为探索和开发全新高效胜肽疗法的全球领先者，以解决患者未满足的医疗需求并改善全球患者的生活质量。Taiyo Pacific...
View ArticleClik here to view.
Study Shows Positive Clinical and Potential Economic Outcomes with V.A.C....
SAN ANTONIO Acelity is pleased to announce the publication of a peer-reviewed study that suggests V.A.C. VeraFlo™ Therapy (NPWTi-d) may be more cost effective than standard V.A.C.® Therapy (NPWT)....
View ArticleClik here to view.
Takeda Announces Abstracts for ADCETRIS® (brentuximab vedotin) in Hodgkin...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced that abstracts of interest from studies on VELCADE® (bortezomib), ADCETRIS® (brentuximab vedotin)...
View ArticleClik here to view.
Avedro Granted Korean Approval for its KXL® Cross-Linking System for Lasik Xtra®
WALTHAM, Mass. Avedro Inc., a Boston-based ophthalmic medical device and pharmaceutical company announces today that it has been granted approval from the South Korean Ministry of Food and Drug...
View ArticleClik here to view.
pSivida Corp. Reports First Quarter FY 2015 Results
WATERTOWN, Mass. pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced financial results for its...
View ArticleClik here to view.
Clik here to view.
R-Tech Ueno: Completion of a Phase I/II Clinical Study of Recombinant Human...
TOKYO R-Tech Ueno (JASDAQ:4573): This is to announce the completion of a Phase I/II clinical study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) for...
View Article